Tenax Therapeutics, Inc. - Common Stock (TENX)

NEW YORK CITY, NY / ACCESS Newswire / October 30, 2026 / Levi & Korsinsky, LLP notifies investors in Tenax Therapeutics, Inc. (NASDAQ:TENX) that Stuart Rich, M.D., Tenax's Chief Medical Officer, is named as an individual defendant facing alleged liability in a securities class action filed on behalf of purchasers of Tenax securities between November 13, 2023 and August 7, 2026. Find out if you could qualify to recover your per-share losses. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.

Investors who lost money on Tenax Therapeutics, Inc. ("Tenax" or the "Company") stock may have claims to recover their losses. Glancy Prongay Wolke & Rotter LLP ("Glancy") today announced a securities fraud investigation on behalf of Tenax Therapeutics, Inc. (NASDAQ: TENX) investors into whether the Company may have violated the federal securities laws. The investigation follows the August 10, 2026 disclosure regarding Tenax Therapeutics, Inc.

Investors who suffered losses on Tenax Therapeutics, Inc. ("Tenax" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today reported that it is conducting a securities fraud investigation on behalf of Tenax Therapeutics, Inc. (NASDAQ: TENX) investors into whether the Company may have violated the federal securities laws. The investigation comes after a August 10, 2026 disclosure concerning Tenax Therapeutics, Inc.

Tenax Therapeutics stock is up on Tuesday after the company revealed an oversubscribed private placement for TENX shares.

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Tenax Therapeutics, Inc. (NASDAQ: TENX) securities between November 13, 2023 and August 7, 2026, inclusive (the “Class Period”), have until December 28, 2026 to seek appointment as lead plaintiff of the Tenax Therapeutics class action lawsuit. Captioned Katz v. Tenax Therapeutics, Inc., No. 26-cv-01264 (M.D.N.C.), the Tenax Therapeutics class action lawsuit charges Tenax Therapeutics and certain of Tenax Therapeutics’ top current and former executives with violations of the Securities Exchange Act of 1934.

NEW YORK, Oct. 29, 2026 (GLOBE NEWSWIRE) --

Tenax Therapeutics, Inc. ("Tenax" or the "Company") investors who lost money may have claims to recover their losses. The Law Offices of Frank R. Cruz today announced it is investigating potential securities fraud claims on behalf of investors in Tenax Therapeutics, Inc. (NASDAQ: TENX), examining whether the Company may have violated the federal securities laws. The investigation centers on the disclosure about Tenax Therapeutics, Inc. on August 10, 2026.

Rosen Law Firm, a global investor rights law firm, announces a class action on behalf of purchasers of securities of Tenax Therapeutics, Inc. (NASDAQ: TENX) between November 13, 2023 and August 7, 2026, inclusive (the “Class Period”). Tenax is a Phase 3, development stage pharmaceutical company.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Tenax Therapeutics, Inc. ("Tenax" or the "Company") (NASDAQ: TENX) and certain officers.   The class action, filed in the United States District Court for the Middle District of North Carolina, and docketed under 26-cv-01624, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Tenax securities between November 13, 2023 and August 7, 2026, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Tenax Therapeutics, Inc. (NASDAQ: TENX) securities between November 13, 2023 and August 7, 2026, inclusive (the “Class Period”). Tenax is a development-stage pharmaceutical company focused on novel cardiopulmonary therapies.

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tenax Therapeutics, Inc. (“Tenax” or “the Company”) (NASDAQ: TENX) for violations of the securities laws.

A single clinical readout drove Tenax Therapeutics (NASDAQ: TENX) shares down approximately 84% to 85% shareholder after the Company disclosed that its Phase 3 LEVEL trial of TNX-103 in PH-HFpEF missed both its primary and key secondary endpoints. If you held TENX shares and suffered a loss, you are encouraged to click here to submit your information. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

Tenax Therapeutics (NASDAQ:TENX) reported that its Phase III LEVEL trial of oral levosimendan in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction, or PH-HFpEF, did not meet its primary endpoint, though the company said subgroup, biomarker and hemody

TENX stock results show that Tenax Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

TENX stock results show that Tenax Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.

Pre-market stock movers are worth checking out as we dive into all of the biggest news sending shares higher and lower on Thursday morning!

Shares of Alcoa Corporation (NYSE: AA) rose sharply in today’s pre-market trading after the company reported better-than-expected sales for its first quarter.

TENX stock results show that Tenax Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.